These trials targeted tumor antigens such as MSLN, glypican-3 (GPC3), CEA, HER2, claudin18.2 (CLDN18.2), B4T2-001, CD70, natural killer group 2 member D ligand (NKG2DL), disialoganglioside (GD2), and mucin1 cell surface-associated C-Terminal (MUC1-C) [40] (Table 3). This evidence concerns the gene CEACAM5 and neoplasm.